Control of Angiogenesis by Galectins Involves the Release of Platelet-Derived Proangiogenic Factors

Julia Etulain¹, Soledad Negrotto¹, María Virginia Tribulatti², Diego Omar Croci³, Julieta Carabelli², Oscar Campetella², Gabriel Adrián Rabinovich⁴,⁵, Mirta Schattner¹*

¹Laboratory of Experimental Thrombosis, Institute of Experimental Medicine, CONICET-National Academy of Medicine, Buenos Aires, Argentina, ²Institute of Biotechnological Investigations, Technologic Institute of Chascomús-National University of San Martín, CONICET, Buenos Aires, Argentina, ³Laboratory of Immunopathology, Institute of Biology and Experimental Medicine (IBYME), CONICET, Buenos Aires, Argentina, ⁴Laboratory of Functional Glycomics, Faculty of Exact and Natural Sciences, University of Buenos Aires, Buenos Aires, Argentina

Abstract

Platelets contribute to vessel formation through the release of angiogenesis-modulating factors stored in their α-granules. Galectins, a family of lectins that bind β-galactoside residues, are up-regulated in inflammatory and cancerous tissues, trigger platelet activation and mediate vascularization processes. Here we aimed to elucidate whether the release of platelet-derived proangiogenic molecules could represent an alternative mechanism through which galectins promote neovascularization. We show that different members of the galectin family can selectively regulate the release of angiogenic molecules by human platelets. Whereas Galectin (Gal)-1, -3, and -8 triggered vascular endothelial growth factor (VEGF) release, only Gal-8 induced endostatin secretion. Release of VEGF induced by Gal-8 was partially prevented by COX-1, PKC, p38 and Src kinases inhibitors, whereas Gal-1-induced VEGF secretion was inhibited by PKC and ERK blockade, and Gal-3 triggered VEGF releaseselectively through a PKC-dependent pathway. Regarding endostatin, Gal-8 failed to stimulate its release in the presence of PKC, Src and ERK inhibitors, whereas aspirin or p38 inhibitor had no effect on endostatin release. Despite VEGF or endostatin secretion, platelet releasates generated by stimulation with each galectin stimulated angiogenic responses in vitro including endothelial cell proliferation and tubulogenesis. The platelet angiogenic activity was independent of VEGF and was attributed to the concerted action of other proangiogenic molecules distinctly released by each galectin. Thus, secretion of platelet-derived angiogenic molecules may represent an alternative mechanism by which galectins promote angiogenic responses and its selective blockade may lead to the development of therapeutic strategies for angiogenesis-related diseases.

Introduction

In the normal adult, angiogenesis, defined as the growth of new blood vessels from preexisting capillaries, is mostly limited to wound healing, pregnancy, and uterine cycling. This process is regulated by a continuous interplay of stimulators and inhibitors that tightly control the normally quiescent capillary vasculature, and their imbalance contributes to numerous malignant, ischemic, and immune disorders [1].

Emerging evidence implicates a key role for platelets in site-specific neovascularization at ischemic tissues and the tumor microenvironment as they are major storage and delivery vehicles for pro- and antiangiogenic growth factors including vascular endothelial growth factor (VEGF), endostatin, and thrombospondin-1 (TSP-1), and cytokines and chemokines, such as stromal-derived factor 1 α (SDF-1α) and IL-8 among others. These proteins are stored together with coagulation factors in platelet α-granules, which upon activation can degranulate and influence the local angiogenic response [2,3]. The recent demonstration of separate packaging of these proteins into morphologically distinct populations of α-granules in megakaryocytes and platelets [4,5,6], and their differential release based on selective engagement of platelet receptors provides mechanism by which platelets can locally and sequentially modulate angiogenesis [7,8,9,10].

Galectins constitute a family of animal lectins that bind β-galactoside residues through their carbohydrate recognition domains (CRD). According to their structure, galectins are classified into three groups: I) “proto-type” galectins, containing a single CRD including galectin (Gal) -1, -2, -7, -10, -13, and -14, II) chimera-type galectins which contain a single CRD and a large amino-terminal non-lectin domain with Gal-3 being its only representative, and III) tandem-repeat type galectins which have two CRD linked by a peptide sequence of variable length and include Gal-4, -8, -9, and -12 [11]. Galectins are expressed in a wide variety of cells and tissues and play an important role in cellular mechanisms including cell signaling, proliferation, migration, apoptosis, and mRNA splicing [12]. Galectins are also associated with different pathologies such as allergies, autoimmune diseases, atherosclerosis, infectious processes, and cancer [13,14,15,16]. In fact, most of these lectins are up-regulated in several types of tumors and this feature correlates with tumor...
progression, aggressiveness and acquisition of a metastatic phenotype [16,17,18]. In addition, increasing evidence indicates that these proteins are also involved in the pathogenesis of cardiovascular diseases [13]. Recent work from our laboratory has shown that both soluble and immobilized Gal-1 and Gal-8 bind and activate platelets, promoting adhesion, aggregation and granule secretion [19,20,21,22].

A growing body of experimental evidence suggest that galectins, mainly Gal-1, -3 and -8, are directly involved in angiogenesis as they induce endothelial cell proliferation, chemotaxis, in vitro capillary tube formation, and in vivo neovascularization [23,24,25,26]. Particularly, the Gal-1-N-glycan axis can link tumor hypoxia to vascularization [26] and promotes VEGF-like signals in tumors that are refractory to anti-VEGF therapy [27].

As platelet activation is stimulated by structurally different galectins, in this study we aimed to elucidate whether the release of platelet-derived proangiogenic molecules represents an additional mechanism by which these lectins promote neovascularization. We found that while all three galectins triggered VEGF release, only Gal-8 induced endostatin secretion. However, despite selective release of platelet-derived angiogenic molecules, platelets stimulated by Gal-1, -3 and -8 promoted angiogenic functional responses. Thus, secretion of platelet-derived angiogenic molecules represents an alternative mechanism underlying the proangiogenic activity of galectins.

Materials and Methods

Reagents

Endostatin and VEGF ELISA kits, and Human angiogenesis Antibody Array G Series 1000 were from Raybiotech, Inc. (Norcross, GA, USA). Go-6983, PPI, SB-203580 and U-0126 were from Enzo Life Sciences International, Inc. (San Diego, CA, USA). Recombinant human Gal-1 was produced essentially as described [28]. The recombinant protein was purified by affinity chromatography on an asialofetuin-agarose column and stored at −20°C. Lipopolysaccharide content of the purified samples was tested using a Gel Clot Limulus Test (Cape Cod, East Falmouth, MA, USA). Human Gal-3-coding DNA sequence was modified to improve its expression in bacteria and a His tag was included to favor purification. The sequence was submitted for synthesis (GeneScript) and the resulting gene subcloned into pTrcHisB (Invitrogen). Recombinant human Gal-0 (M isoform) was obtained as described previously [20]. Recombinant human Gal-3 and mouse gal-1-8-1 chimera were produced as described previously [29]. Growth factor-reduced Matrigel was obtained from Becton Dickinson Biosciences (Bedford, MA, USA). MTT [3-(4,5-dimethylthiaxol-2-yl)-2,5-diphaenyltetrazolium bromide] was from Promega Corporation (Madison, WI, USA). Recombinant VEGF-A, goat anti human VEGFR2/KDR/Flik-1, mouse anti human VEGF-A neutralizing antibody, and the corresponding irrelevant IgGs were purchased from R&D Systems (Minneapolis, MN, USA). Rabbit anti-human EGF neutralizing antibody and control IgG were obtained from Cell Signaling Technology (Danvers, MA, USA).

Preparation of Human Platelets

Blood samples were obtained from healthy donors who had not taken nonsteroidal antiinflammatory drugs in the 10 days before sampling. This study was conducted according to the principles of the Declaration of Helsinki. The study was approved by the Institutional Review Board of the National Academy of Medicine, Buenos Aires, Argentina. All patients provided written informed consent for the collection of samples and subsequent analysis. Blood was drawn directly into plastic tubes containing sodium citrate (3.8%). Platelet rich plasma (PRP) was obtained by centrifugation of the blood samples (180 × g for 10 min). For washed platelet (WP) suspensions, PRP was centrifuged in the presence of prostacyclin (PGI2) (75 nM) (890 × g for 10 min), and the platelets were washed in washing buffer (140 mM NaCl, 10 mM NaHCO3, 2.5 mM KCl, 0.5 mM Na2HPO4, 1 mM MgCl2, 22 mM sodium citrate, 0.55 mM glucose, 0.35% BSA, pH 7.4).

Figure 1. Gal-1, Gal-3 and Gal-8 differentially control the release of VEGF and endostatin by platelets. A) WPs were stimulated with different concentrations of Gal-1, -3 or -8 for 5 min (n = 4; *P < 0.05 vs. unstimulated). B) WPs (500 μl at 4 × 10^7/ml) were lysed with Triton X100 (0.1%) and sonicated (n = 4). The amounts of VEGF and endostatin in supernatants were quantified by ELISA.

doi:10.1371/journal.pone.0096402.g001
Finally, platelets were resuspended in Tyrode's buffer (134 mM NaCl, 12 mM NaHCO_3, 2.9 mM KCl, 0.34 mM Na_2HPO_4, 1 mM MgCl_2, 10 mM HEPES, 5 mM glucose, 0.35% BSA, pH 7.4) at a concentration of 4×10^8/ml, unless otherwise stated. CaCl_2 (1 mM) was added 1 min before platelet stimulation.

**ELISA Assays for VEGF and Endostatin Release**

Briefly, WPs (500 μl at 4×10^6/ml) were stimulated with Gal-1, -3 or -8 for 5 min. Cell suspensions were centrifuged twice (first at 1100×g for 5 min and then at 9300×g for 5 min) in the presence of PGI_2 (75 nM) and supernatants were stored at −80°C until assayed. In some experiments, WPs were incubated for 30 min before stimulation with aspirin (ASA, 500 μM), or with specific inhibitors of PKC (Go-6983, 1 μM), Src (PP1, 5 μM), p38 (SB-203580, 25 μM) and pERK (U-0126, 10 μM). The concentrations of the inhibitors were selected from pilot studies and were the minimal that completely suppressed phosphorylation of the specific target proteins as previously described [30]. The concentration of ASA used was the minimal that abrogated arachidonic acid-induced platelet aggregation. To obtain platelet lysates, platelet pellets were suspended with distilled in H_2O in presence of Triton X100 (0.1%) and cells were hydrolyzed by sonication. Ionic concentration was restored by addition of Tyrode's buffer (10X) and supernatants were obtained. Release of VEGF and endostatin was measured by using commercial ELISA kits according to the manufacturer's instructions.

**Human Angiogenic Factors Array**

WPs (500 μl at 4×10^6/ml) were stimulated with Gal-1, -3 or -8 for 5 min. Cell suspensions were centrifuged twice (first at 1100×g for 5 min and then at 9300×g for 5 min) in the presence of PGI_2.
Angiogenesis Mediated by Galectin-Treated Platelets

Figure 3. Different signaling pathways mediate the release of VEGF and endostatin induced by individual galectins. WPs were incubated with specific inhibitors of cyclooxygenase-1 (ASA, 500 μM), p38 (SB-203580, 25 μM), PKC (Go-6983, 1 μM), Src (PP1, 5 μM), or pERK (U-0126, 10 μM) for 30 min. Then, platelets were stimulated with the EC50 of Gal-1 (0.5 μM), Gal-3 (1 μM) and Gal-8 (0.25 μM) for 5 min. Results are expressed as percentage of inhibition relative to similar treatment without inhibitor (n = 3; P < 0.05). doi:10.1371/journal.pone.0096402.g003

(75 μM) and supernatants were stored at −80°C until assayed. Release of angiogenic factors was measured by using commercial array kits according to the manufacturer’s instructions.

Endothelial Cell Culture

Human microvascular endothelial cells 1 (HMEC-1) were obtained from the Center of Disease Control and Prevention (CDC, Atlanta, USA). Cells were grown in RPMI supplemented with fetal bovine serum (10%), L-glutamine (2 mM) and penicillin (100 U/ml) at 37°C in a humidified 5% CO2 incubator. In selected experiments VEGFR2/KDR was blocked with an anti-VEGFR2 neutralizing monoclonal antibody. Some experiments were also performed in the presence of VEGF-A or EGF receptor (EGFR) neutralizing antibodies.

Endothelial Cell Proliferation

Cell proliferation was determined by using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Briefly, HMEC-1 (250 μl at 2.5 × 10^4/well) were incubated in 48-well plates with sucrose (50 mM) or lactose (50 mM) for 30 min in the presence or absence of the VEGF2 neutralizing antibody (2 μg/ml). The medium was then aspirated and cells were incubated with platelet supernatants (250 μl) previously stimulated with galectins or control medium without platelets supplemented with penicillin/streptomycin and polymyxin (7 μg/ml). Positive and negative controls included Tyrode’s buffer with or without VEGF (20 ng/ml). After 18 h of incubation, MTT was added to each well, and cells were further incubated for 3 h at 37°C. Stop solution was added and aliquots of each well were transferred to a 96-well plate and absorbance at 570 nm was measured. The number of cells was extrapolated from a concentration-cell curve performed for each experiment [30].

In vitro Tube Formation Assay

Prechilled 48-well microtiter plates were coated with growth factor-reduced Matrigel for 2 h at 37°C. HMEC-1 (2.5 × 10^4) in Tyrode’s were loaded in each well, preincubated with sucrose (50 mM) or lactose (50 mM) in the presence or absence of a neutralizing anti-VEGFR2 antibody (2 μg/ml), anti-VEGF-A (2 μg/ml), or anti-EGFR (20 μg/ml) for 30 min, and then incubated in the presence of VEGF (20 ng/ml) or EGF (20 ng/ml) (positive controls), or platelet supernatants obtained after stimulation with galectins supplemented with polymyxin (7 μg/ml) for 18 h. Tube formation was analyzed under an inverted light microscope, and the number of branch points in four non-overlapping fields was determined [30].

Statistical Analysis

The results are expressed as mean ± SEM and were analyzed by one-way analysis of variance followed by Newman-Keuls multiple comparison test to determine significant differences between groups. A P value lower than 0.05 was considered statistically significant.

Results

Differential Release of VEGF and Endostatin Induced by Gal-1, -3 and -8

Release of angiogenesis-modulating factors from platelet granules is one of the mechanisms by which platelets can modulate vessel formation [3]. As galectins can stimulate both neovascularization and platelet activation, we examined whether representative members of the three subfamilies of galectins including Gal-1 (‘proto-type’), Gal-3 (‘chimera-repeat’) or Gal-8 (‘tandem-repeat’) can trigger the release of platelet-derived molecules that promote or inhibit angiogenesis such as VEGF or endostatin, respectively. We found that while Gal-8 induced the secretion of VEGF and endostatin, Gal-1 and -3 only promoted the release of VEGF. Of note, even at high concentrations (up to 10 μM), Gal-1 and -3 failed to induce endostatin secretion (Figure 1A). Based on EC50 values, we found that Gal-8 induced higher secretion of VEGF (0.25±0.05 μM) than Gal-1 (0.50±0.05 μM) or Gal-3 (1.0±0.3 μM).

The total amount of intraplatelet VEGF and endostatin was measured in platelet lysates (Figure 1B). Platelet activation induced by each galectin led to the release of 50% of the stored VEGF, whereas Gal-8 induced the secretion of 75% of total endostatin.

The secretion of VEGF induced by each galectin as well as the secretion of endostatin induced by Gal-8 were completely prevented by lactose, a galectin-specific competitor, but not by sucrose, suggesting that these effects involved recognition of glycan residues on the platelet surface (Figure 2A). To examine whether the selective release of VEGF and endostatin induced by Gal-1 and -3 could be associated with differences in the kinetics of platelet stimulation, treatment was extended from 5 to 60 min. Moreover, in order to induce the maximal release of granule cargo, these assays were performed under stirring. Under these conditions, VEGF release was slightly enhanced by galactins; however Gal-1 and Gal-3 still failed to induce endostatin secretion (Figure 2B). A possible explanation for the differential release of endostatin after platelet stimulation with Gal-1, -3 or -8 might rely on the structural differences between the three lectins. To test this hypothesis, the secretion of angiogenesis-related molecules was...
Figure 4. Platelets stimulated by galectins trigger endothelial cell proliferation and capillary-like tube formation. HMEC-1 were preincubated in 48-well plates in the presence of lactose (50 mM), and with anti-VEGFR2, anti-VEGF-A (2 μg/ml), goat or mouse irrelevant IgGs during 30 min. Since proliferation or capillary tube formation were not modify by the different IgGs we only show the values obtained in the absence of antibodies. Then, cells were incubated during 18 h with VEGF (20 ng/ml) (positive control) or with supernatants from platelets that were unstimulated or stimulated with the minimal concentration of galectin to induce maximal VEGF release. A) Endothelial cell proliferation was determined by addition of MTT reagent. Reaction was stopped and the absorbance was determined at 570 nm. B) Tube formation in Matrigel-coated wells was analyzed under an inverted light microscope, and the number of branch points in four non-overlapping fields was determined. The photographs show one individual field of endothelial cells incubated with or without platelet supernatants (n = 4; *P < 0.05 vs. unstimulated, #P < 0.05 vs. without anti-VEGFR2 mAb).

doi:10.1371/journal.pone.0096402.g004
induced with a protein chimera designed by connecting two sequences of full-length Gal-1 with the linker peptide from Gal-8L isoform, resulting in a combination of the Gal-1 CRD sequence with the Gal-8 dimeric structure. Like Gal-1, the chimeric lectin failed to induce endostatin release suggesting that the dissimilar responses exerted by galectins are not due to their structural composition but probably to the specific CRDs (Figure 2C).

Figure 5. Gal-1, -3 or -8 induce a differential pattern of angiogenic regulators release in platelets. A) WPs were stimulated with Gal-1 (5 μM), Gal-3 (5 μM) or Gal-8 (1 μM) for 5 min. The release of angiogenic factors was determined using a commercial array kit. Release of each molecule induced by individual galectins is expressed as fold increase over unstimulated controls (n = 2). B) HMEC-1 were preincubated with anti-EGFR antibody (20 μg/ml) or irrelevant IgG during 30 min. Then, cells were incubated for 18 h with EGF (20 ng/ml) or with supernatants from unstimulated or galectin-stimulated platelets. Endothelial cell proliferation and tube formation were analyzed (n = 3; *P<0.05 vs. unstimulated, #P<0.05 vs. without neutralizing antibody (Ab)).

doi:10.1371/journal.pone.0096402.g005

The Release of VEGF and Endostatin Induced by Galectins is Regulated by different Signaling Pathways

To investigate the intracellular signals triggered by galectins to induce VEGF and endostatin release, in the next set of experiments platelet stimulation was performed in the presence of specific inhibitors of the major signaling pathways involved in platelet granule secretion including cyclooxygenase (aspirin), p38
analyzed the pattern of secretion of platelet-derived angiogenic factors triggered by Gal-1, -3 or -8 using an angiogenic microarray kit (Figure 3 and Table S1). Factors increasing at least 1.5 fold were included in the analysis. Remarkably, epidermal growth factor (EGF) was the major factor released upon platelet stimulation by the three galectins. The amounts of other factors including PDGF-BB, angioatin and VEGF, were equivalent in supernatants from platelets treated with either Gal-1, -3 or -8, whereas secretion of other factors was selectively modulated by each individual galectin. While Gal-1 induced maximal release of IL-6 and MMP-1, Gal-3 induced maximal release of I-308, IL-1β and MMP-9 (Figure 5). Moreover, supernatants of platelet stimulated by Gal-8 contained more EGF, ENA-78, bFGF, GRO, TIMP-2, IFN-γ, and endostatin than those from platelets stimulated by Gal-1 or -3 (Figure 5). Altogether these findings suggest that each galectin differentially controls the release of platelet-derived angiogenic factors, which may act in concert to promote angiogenesis.

To further identify the relevant mediator responsible for the proangiogenic activity of platelets, angiogenic responses were induced by platelet supernatants that were previously stimulated with galectins in the presence of an anti-EGF receptor antibody. Similar to VEGF, blockade of EGF activity resulted in moderate inhibition of both endothelial cell proliferation and capillary-like tube formation (Figure 3B). Moreover, simultaneous suppression of VEGF and EGF, did not exert additive or synergic inhibitory effects in plaquelet-mediated angiogenesis (Figure S2), suggesting that the combined action of other factors accounts for the observed effect.

Discussion

In this study we provide evidence of an additional mechanism, i.e. the release of platelet-derived angiogenic molecules, by which galectins promote angiogenesis. Although non-structurally related galectins such as Gal-1, -3 and -8 selectively modulated secretion of VEGF and endostatin from platelet α-granules, platelet activation induced by each galectin resulted in a VEGF-independent proangiogenic response, which was likely due to the combined action of several angiogenic mediators.

The ability of all three galectins to trigger VEGF release, but only Gal-8 being able to induce endostatin secretion is in agreement with the new paradigm of platelet α-granule secretion. This new paradigm supports the notion that not all α-granules are morphologically similar, they store different cargo proteins, and they can be selectively activated to release molecules with opposite roles. Recent studies have focused on this novel paradigm in terms of secretion of pro- and antiangiogenic molecules triggered by agonists such as thrombin receptor agonists, ADP or thromboxane A₂ [5,7,8,9,10]. Here we demonstrate that the differential release of VEGF or endostatin is not restricted to classical platelet agonists but can also be induced by non-canonical platelet activators such as galectins. Although the structure and dynamics of α-granule secretion is still under debate, different hypotheses seem to converge in the notion that selective signaling pathways might be involved in the regulation of α-granule content exocytosis. In this sense, differences in the release of pro- and antiangiogenic molecules induced by galectins were not associated with differences in the kinetics of secretion or to structural divergences, but rather with distinct signaling pathways triggered by each galectin. While Gal-1 triggered PKC and ERK activation to induce VEGF release, Gal-3 activated a PKC-dependent pathway to stimulate the same biological response. On the other hand, release of VEGF
by Gal-8 required not only the activation of COX-1 but also activation of PKC, p38, and Src kinases.

Interestingly, conditioned media derived from platelets activated by each galectin all elicited endothelial cell proliferation and capillary-tube formation, two cellular events linked to angiogenesis. These data indicate that regardless of the differential effect of Gal-1, -3 or -8 on the secretion of angiogenic factors, galectin-induced platelet activation results in promotion of an angiogenic phenotype.

In contrast to the traditional role of VEGF in platelet-mediated angiogenesis, we found that suppressing VEGF signaling using anti-VEGFR2 or anti-VEGF-A antibodies, did not considerably alter endothelial cell responses, suggesting that this factor could be dispensable for the angiogenic activity of platelets when activated in response to galectin stimulation. Interestingly, we found that blockade of EGF, the major angiogenic factor released from platelets upon stimulation with galectins partially inhibited angiogenesis mediated by supernatants from galectin-stimulated platelets. Moreover, a similar degree of inhibition was observed when the activity of both VEGF-A and EGF was inhibited. These results suggest that the angiogenic activity mediated by platelets is a complex process that appears to be due to the combined activity of several angiogenesis-related molecules released from galectin-stimulated platelets. In this regard, we recently demonstrated that platelet-induced angiogenesis by thrombin also involves the activity of several angiogenic modulators but not VEGF [30].

Altogether, these studies suggest that platelets can release pro- and antiangiogenic substances and different agonists can selectively regulate this process. Moreover, it could be speculated that in the activated normal or tumor endothelium galectins are differentially regulated [31,32,33] and contribute to tumor vascularization by stimulating the release of diverse proangiogenic mediators. Interestingly, the net biological effect appears to be proangiogenic regardless of the platelet agonist used. This implies that the proangiogenic effect of galectins via platelets contributes to a positive feedback that influences tumor progression. However, we do not rule out the possibility that, in an alternative pathologic setting the contribution of platelet-derived antiangiogenic mediators might gain relevance. In this sense, it has been demonstrated that concentration of angiogenesis regulatory proteins in platelets, although relatively constant and stable under physiologic conditions, is substantially modified by the presence of a growing tumor. Specifically it has been shown that changes in major platelet antiangiogenic factors such as platelet-associated PF-4 [34] and TSP-1 [35] are upregulated in platelets of tumor-bearing mice. Regarding TSP-1, this phenomenon has been found to be a consequence of both, increased levels of TSP-1 mRNA in megakaryocytes, as well as increased numbers of these cells in the bone marrow of tumor-bearing mice [35]. Thus, it has been suggested that the production and delivery of antiangiogenic molecules by platelets might serve as a critical early host response to suppress vascular supply during tumor growth, emphasizing the potential value of these molecules as indicators for tumor growth and regression. Since the early antiangiogenic response triggered by platelets could be overcome during tumor progression inducing a switch toward a platelet proangiogenic phenotype, more data are needed to establish whether the platelet proteome changes after longer periods following the establishment of a tumor. Supporting these findings, it has been recently demonstrated that the tumor cell line MCF-7 and the platelet agonist ADP, induce the release of VEGF but not endostatin from platelets, thus promoting migration and tubulogenesis in endothelial cells [9]. In addition, conditioned medium from MCF-7-stimulated platelets contain a greater number of proangiogenic factors compared to conditioned medium from ADP-stimulated platelets suggesting that the process of platelet activation with MCF-7 cells involves activation of additional mechanisms rather than just ADP [9]. As MCF-7 cells express several members of the galectin family, including Gal-1, -3 and -8 [36], and GPIbα/H/α1 and GPIbα are essential for transducing galectin signaling [20,22], platelet activation mediated by galectins could have evolved as a mechanism complementary to ADP to promote a tumor proangiogenic phenotype.

In summary, our data highlight an additional mechanism, based on the secretion of platelet-derived angiogenic factors, by which galectins contribute to angiogenesis. As galectins are up-regulated in endothelial cells and tumors in angiogenic-related disorders, and galectin stimulation activates platelets to secrete soluble proangiogenic factors, selective targeting of these pathways may contribute to delineate novel therapeutic approaches in order to promote tissue regeneration and attenuate atherosclerosis, ischemic ulcers, diabetes and cancer.

Supporting Information

Figure S1 Lactose inhibits endothelial cell proliferation and capillary-like tube formation induced by galectins.

A) HMEC-1 (2.5 × 10^4/well) were preincubated in 48-well plates in the presence of lactose (50 mM) for 30 min. Then, cells were incubated in buffer Tyrode’s with or without VEGF-A (20 ng/ml) (positive control) or with Gal-1, -3 or -8 at the indicated concentrations. After 18 h of incubation, MTT reagent was added to each well. Reaction was stopped and the absorbance was determined at 570 nm (n = 3; *P<0.05 vs. unstimulated). B) HMEC-1 (2.5 × 10^5) were preincubated in Matrigel-coated wells in the presence of lactose for 30 min. Then, cells were incubated with VEGF-A (positive control) or with Gal-1, -3 or -8 at the indicated concentrations for 18 h. Tube formation was analyzed under an inverted light microscope and the number of branch points was determined in four non-overlapping fields (n = 3; *P<0.05 vs. unstimulated).

(TIF)

Table S1 Platelet-derived angiogenesis modulators measured by the Antibody Array G Series 1000 from Raybiotech (n = 2).

(DOC)

Author Contributions

Conceived and designed the experiments: JE. SN MS OC GAR. Performed the experiments: JE. Analyzed the data: JE. SN MS OC GAR. Contributed
References

1. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932–936.
2. Rafii DC, Paalda B, Butler J, Jin DK, Lyden D (2008) Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 28: 217–222.
3. Parzer J, Langer HF (2012) Platelets in angiogenesis. Curr Vase Pharmacol 10: 570–577.
4. van Nispen tot Panmerden H, de Haas F, Geerms W, Posthuma G, Dijk S, et al. (2010) The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes. Blood 116: 1147–1156.
5. Chatterjee M, Huang Z, Zhang W, Jiang L, Hultenby K, et al. (2011) Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 117: 3907–3911.
6. Sehgal S, Storrie B (2007) Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 5: 2009–2016.
7. Ma L, Perini R, McInkton W, Dicya M, Klein A, et al. (2005) Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102: 216–220.
8. Italiano JE Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, et al. (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111: 1227–1233.
9. Battinelli EM, Markens RA, Italiano JE, Jr. (2011) Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118: 1359–1369.
10. Bambace NM, Levin JE, Holmes CE (2010) The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 21: 85–93.
11. Rabinirovich GA, Baum LG, Tinari N, Paganelli R, Naloli C, et al. (2002) Galectins and their ligands: amplifiers, silencers or tumours of the inflammatory response? Trends Immunol 23: 313–320.
12. Yang RY, Rabinovich GA, Liu FT (2006) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10: e17.
13. Al-Amsari S, Zerbovs GJ, Slat KH, Peppelenbosch M, Tio RA (2009) Galectins in atherosclerotic disease. Trends Cardiovasc Med 19: 164–169.
14. Liu FT, Rabinovich GA (2010) Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 1183: 158–182.
15. Nording LV, Ferretti M, Cooper D (2009) Endogenous galectins and the control of the host inflammatory response. J Endocrinol 201: 169–184.
16. Rubinstein N, Akbarov M, Zwirner NW, Toscano MA, Ilarregui JM, et al. (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5: 241–251.
17. Bidon-Wagner N, Le Penne JP (2004) Human galectin-8 isoforms and cancer. Glycobiology 19: 557–563.
18. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29–41.
19. Romaninik MA, Negrotto S, Campetella O, Rabinovich GA, Schattner M (2011) Identification of galectins as novel regulators of platelet signaling and function. IUBMB Life 63: 521–527.
20. Romaninik MA, Tribulati MV, Cattaneo V, Lapponi MJ, Molinias FC, et al. (2010) Human platelets express and are activated by Galectin-1. Biochem J 435: 535–547.
21. Pacienza N, Posner RG, Bianco GA, D’Arri LP, Croci DO, et al. (2008) The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. Fasebj J 22: 1113–1123.
22. Romaninik MA, Croci DO, Lapponi MJ, Tribulati MV, Negrotto S, et al. (2012) Binding of galectin-1 to alphabeta(3) integrin triggers “outside-in” signals, stimulates platelet activation, and controls primary hemostasis. Fasebj J 26: 2788–2798.
23. Nangia-Makkar P, Honjo Y, Sarvis R, Akahani S, Hogan V, et al. (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156: 899–909.
24. Thijssen VL, Postel R, Brandwijk RJ, Ding RS, Neesmolca I, et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 103: 15975–15980.
25. Delgado VM, Nogues LG, Colombo LL, Troncoo MF, Fernandez MM, et al. (2011) Modulation of endothelial cell migration and angiogenesis: a novel function for the “tandem-repeat” lectin galectin-8. Fasebj J 25: 242–254.
26. Croci DO, Salatino M, Rubinstein N, Cerfani JP, Cavallin LE, et al. (2012) Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma. J Exp Med 209: 1915–2000.
27. Croci DO, Cerfani JP, Dalto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, et al. (2014) Glycousylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors. Cell 156: 899–909.
28. Hribabashi J, Hashidate T, Araya Y, Nishi N, Nakamura T, et al. (2002) Oligosaccharide specificity of galectin: a search by frontal affinity chromatography. Biochim Biophys Acta 1572: 232–254.
29. Tribulati MV, Figini MG, Carabelli J, Cattaneo V, Campetella O (2012) Redundant and antagonist functions of galectin-1, -3, and -8 in the elicitation of T cell responses. J Immunol 188: 2991–2999.
30. Enailin J, Fondevala C, Negrotto S, Schattner M (2013) Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol 170: 255–265.
31. Thijssen VL, Hulmans S, Griffioen AW (2008) The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 172: 545–553.
32. Heuschken R, Schullek IA, van Beijnum J, Griffioen AW, Thijssen VL (2014) Endothelial LGAL8 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta 1842: 284–292.
33. Thijssen VL, Barkan B, Shoji H, Aries EM, Mathieu V, et al. (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70: 6216–6224.
34. Cerveri D, Yip TT, Bhattacharya N, Pedrot NV, Peterson J, et al. (2008) Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111: 1201–1207.
35. Zaslavsky A, Back KH, Lynch RC, Short S, Grillo J, et al. (2010) Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of tumor angiogenesis. Blood 115: 4605–4613.
36. Satelli A, Rao PS, Gupta PK, Lockman PR, Silvernagpal KS, et al. (2008) Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep 19: 587–594.